Munich – November 09, 2026 -- People with cancer and their relatives in Germany can call a free, confidential expert hotline on 0800 2030040, Monday to Friday from 8 a.m. to 6 p.m. The service, called "Halt bei Krebs," is run by GSK and staffed by medical professionals.
Medical staff explain diagnoses, therapies and side effects
The hotline is aimed in particular at people with multiple myeloma, myelofibrosis, ovarian cancer or uterine cancer, and at their families. Staff explain the disease, its treatment, symptoms and side effects, and help callers relate that information to their own situation.
The aim is to help patients understand their illness, prepare for doctor appointments and make informed decisions together with their treatment team. On request, the team also points callers to self-help groups and associations. Email support and the service's website supplement the hotline.
Ines Verena Eggert, Director Patient Relations at GSK Germany, says people with cancer and their relatives should not feel alone with their questions.
Medication questions require verification, and the hotline does not replace a doctor
Staff can give information about medication only if callers raise their prescription themselves and can verify it, for example with a batch number or an access code. The hotline complements medical advice but does not replace it. For questions about an individual treatment, the team refers callers to their treating physician. Psycho-oncological or psychotherapeutic care is also not replaced.
Callers get help finding and understanding clinical trials
Clinical trials are a second focus of the hotline. Staff help callers search for potentially suitable studies and answer questions about requirements, participation, process and safety. A separate website lets interested people look up GSK's clinical trials.
Kai Richter, Vice President and Country Medical Director at GSK Germany, says trials can offer patients an additional treatment option. He stresses that easy access to understandable information matters. Whether participation makes sense in an individual case is something patients clarify with their treating physicians.